Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.48 |
| ▸ | TDO2 | P48775 | 13/20 | 0.48 |
| ▸ | IDO2 | Q6ZQW0 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807692 | 0.88 | IDO1 (0.60) | IDO1TDO2IDO2GPR119 | |
| SCHEMBL9223866 | 0.84 | TDO2 (0.46) | IDO1TDO2IDO2MAPTMAP4K4 | |
| SCHEMBL12289910 | 0.81 | IDO1 (0.49) | IDO1TDO2IDO2 | |
| SCHEMBL9102861 | 0.79 | TDO2 (0.49) | IDO1TDO2IDO2 | |
| SCHEMBL4585590 | 0.78 | IDO1 (0.48) | IDO1TDO2IDO2MAPTALDH1A1 | |
| SCHEMBL9105433 | 0.77 | TDO2 (0.61) | IDO1TDO2IDO2 | |
| SCHEMBL9104271 | 0.70 | TDO2 (0.49) | IDO1TDO2IDO2 | |
| SCHEMBL16824991 | 0.70 | MAPT (0.55) | MAPTMAP4K4ALDH1A1LMNAHDAC1 | |
| SCHEMBL21261237 | 0.70 | MAPT (0.55) | MAPTMAP4K4ALDH1A1LMNAHDAC1 | |
| SCHEMBL13419734 | 0.70 | MAPT (0.55) | MAPTMAP4K4ALDH1A1LMNAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012987-B2 | Indolo[2,1-b] quinazole-6,12-dione antimalarial compounds and methods of treating malaria therewith | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2011-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | IDO1 20/4885TDO2 66/4885IDO2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.